2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Fatigue
21
Neoplasms
6
cyclopia sequence
4
Glioma
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sleepiness
2
Sleep Initiation and Maintenance Disorders
2
Pain
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Sleep Wake Disorders
1
Prostatic Neoplasms
1
Parasomnias
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Nervous System Neoplasms
1
Multiple Myeloma
1
Meningioma
1
Melanoma
1
Lymphoma, B-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Laryngeal Diseases
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioblastoma
1
Esophageal Neoplasms
1
Interventions
Exercise
6
Transcranial Direct Current Stimulation
4
Neuropsychological Tests
4
Walking
3
Memantine
3
Tablets
2
Standard of Care
2
Patient Reported Outcome Measures
2
Methods
2
Electroencephalography
2
Drug Therapy
2
Donepezil
2
Cognitive Behavioral Therapy
2
mazdutide
1
lithium sulfate
1
lime
1
fasudil
1
enzalutamide
1
blueberry extract
1
beta Carotene
1
acetaminophen, aspirin, caffeine drug combination
1
XENP 1595
1
Vitamin E
1
Vitamin D
1
Ultraviolet Therapy
1
Transcranial Magnetic Stimulation
1
Time
1
Therapeutics
1
Tai Ji
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cognitive Dysfunction
×
Modafinil
×
Clear all
NCT05333250
2026-01-13
MODIFY
Ottawa Hospital Research Institute
Phase 1/2
Recruiting
40 enrolled